Placebo News and Research

RSS

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that the first patient has been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

3 Feb 2011

Shire announces Health Canada's approval of VYVANSE for treatment of ADHD in adolescents and adults

Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VYVANSE® (lisdexamfetamine dimesylate capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents and adults.

2 Feb 2011

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

The Company announced that the University of Rochester in concert with ADEPT has selected the study results from the KRN5500 Phase 2 study to be presented at its March 25-26, 2011 conference. The presentation is entitled, "Management of Placebo Response in a Randomized Trial of KRN5500 in Patients with Neuropathic Pain and Cancer."

2 Feb 2011

Nitrate boosts efficiency of mitochondria

The spinach-eating cartoon character Popeye has much to teach us, new research from the Swedish medical university Karolinska Institutet shows. The muscles' cellular power plants - the mitochondria - are boosted by nitrate, a substance found in abundance in vegetables such as lettuce, spinach and beetroot.

2 Feb 2011

Daily probiotic may help prevent upper respiratory tract infections in athletes: Research

Researchers at Loughborough University have revealed that a simple, daily probiotic might help prevent athletes catching colds during their training and competition.

2 Feb 2011

BioMarin commences GALNS Phase 3 trial in patients with Morquio A Syndrome

BioMarin Pharmaceutical announced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase, intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA, also called Morquio A Syndrome.

1 Feb 2011

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Medicago, a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

1 Feb 2011

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

1 Feb 2011

Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the United States Food and Drug Administration (FDA) has issued a complete response letter dated January 31, 2011 regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.

1 Feb 2011

Elsevier announces publication of two position statements from EMAS in Maturitas journal

Elsevier announced today the publication of two further important position statements from the European Menopause and Andropause Society in the journal Maturitas on common management problems in the post-reproductive health of women.

1 Feb 2011

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ToleroMune(R) cat allergy treatment significantly reduced patients' symptoms in a recently completed, large-scale phase II clinical trial. The study also confirmed the treatment's highly favourable safety profile.

1 Feb 2011

Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief

OXIS International, today announced highly favorable final results from an initial clinical study to assess the beneficial effects of its patent-pending ERGOFLEX joint health formula, launched commercially in December 2010.

1 Feb 2011

Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease

BELLUS Health announced today the results of the phase I clinical study for NRM8499, a prodrug of tramiprosate, intended for the treatment of Alzheimer's disease.

1 Feb 2011

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

AVANIR Pharmaceuticals, Inc. today announced that NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) is now available by prescription in the United States. NUEDEXTA is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA).

1 Feb 2011

MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults

Allergan, and MAP Pharmaceuticals, today announced a collaboration within the United States for LEVADEX, a self-administered, orally inhaled therapy that has completed Phase III clinical development for the treatment of acute migraine in adults.

31 Jan 2011

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Maxygen, a biotechnology company focused on the development of improved protein drugs, today announced the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic that is being developed by Perseid Therapeutics LLC, Maxygen's majority-owned subsidiary, in collaboration with Astellas Pharma Inc. for the treatment of rheumatoid arthritis and potentially other autoimmune indications.

31 Jan 2011

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.

31 Jan 2011

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.

29 Jan 2011

Exposure to infections in early childhood can protect child from eczema later in life: Study

Exposure to worm infections in the womb may protect a newborn infant from developing eczema, a study funded by the Wellcome Trust suggests. A large trial in Uganda showed that treating a pregnant woman for worm infections increased her child's chances of developing the allergic skin disease.

29 Jan 2011

Placebo News and Research

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

Shire announces Health Canada's approval of VYVANSE for treatment of ADHD in adolescents and adults

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

Nitrate boosts efficiency of mitochondria

Daily probiotic may help prevent upper respiratory tract infections in athletes: Research

BioMarin commences GALNS Phase 3 trial in patients with Morquio A Syndrome

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA

Elsevier announces publication of two position statements from EMAS in Maturitas journal

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief

Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

Exposure to infections in early childhood can protect child from eczema later in life: Study

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News